Because every second counts
Discover faster* administration with OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy), an immunotherapy treatment given by injection that is FDA approved to treat most cancer types approved for OPDIVO® (nivolumab).†
Actor portrayals.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
†OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab).
About OPDIVO Qvantig
OPDIVO Qvantig is an under-the-skin immunotherapy injection of OPDIVO and hyaluronidase. OPDIVO Qvantig includes an enzyme (hyaluronidase) which improves the way medicines are absorbed into the body when injected under the skin.
Otherwise, it still works the same way OPDIVO does with your immune system to help your body fight cancer. Another difference is that the OPDIVO Qvantig injection takes 3-5 minutes* compared to about 30 minutes for OPDIVO IV, so you will be finished with the administration faster.* Talk to your doctor to see if OPDIVO Qvantig is right for you.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig may not be used in combination with ipilimumab.
Talk to your doctor to see if OPDIVO Qvantig is right for you; it is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig may not be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary.
It’s important to talk to your doctor to discuss the most appropriate treatment for you. OPDIVO Qvantig (nivolumab and hyaluronidase-nvhy) is FDA-approved, and may be an alternative option to intravenous (IV) OPDIVO (nivolumab) for certain patients. It is given through a subcutaneous (under-the-skin) injection. OPDIVO Qvantig received by injection could be an option for people who are on OPDIVO treatment by itself (monotherapy). OPDIVO Qvantig could also be an option for people who are on OPDIVO in combination with cabozantinib or chemotherapy. OPDIVO Qvantig cannot be prescribed in combination with YERVOY (ipilimumab).
OPDIVO Qvantig is not approved for all the indications of OPDIVO IV. Please see Full Prescribing Information for the list of indications. Please see the full list of indications for OPDIVO Qvantig and OPDIVO IV.
When you receive OPDIVO Qvantig, it is injected subcutaneously under the skin in your stomach area (abdominal injection site) or thigh area (thigh injection site) instead of into a vein. The injection will be given by a healthcare professional over a period of 3-5 minutes.*
While you might think of an injection as a “shot” like a flu shot, an injection to administer OPDIVO Qvantig is a bit different. It is given more gradually (in 3-5 minutes*) than an injection would be given for a flu shot or other type of vaccine.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary.
OPDIVO Qvantig is administered at a subcutaneous injection site, which is under your skin, instead of directly into a vein. OPDIVO Qvantig can be administered directly into the skin of your stomach area (abdominal injection site) or thigh area (thigh injection site).
No, you will not need a port for OPDIVO Qvantig, since it is received by injection under the skin and not by infusion. However, if there are additional medications that you will receive (for example, chemotherapy), you may still need a port for those. Talk to your doctor for more details based on your individual treatment plan.
OPDIVO Qvantig can cause problems that can sometimes become severe or can lead to death. Serious side effects may include lung problems; intestinal problems; liver problems; hormone gland problems; kidney problems; skin problems; problems in other organs and tissues; and complications of stem cell transplant that uses donor stem cells (allogeneic). Call or see your healthcare provider right away for any new or worsening signs or symptoms.
Tell your doctor immediately about all side effects, including any changes in how you are feeling, so your doctor can help you address them right away. It’s a good idea to keep a journal to write down anything unusual, and to help you and your doctor discuss potential symptoms of side effects. This side effects tracker may help. MedWatch can help you learn more about side effects and how to report them.
Switching from OPDIVO IV to OPDIVO Qvantig
With OPDIVO Qvantig, you could avoid needing access to a vein for your treatment, since OPDIVO Qvantig is injected under the skin. OPDIVO Qvantig includes a natural enzyme (hyaluronidase) which improves the way medicines are absorbed into the body when injected under the skin. Another difference is that the OPDIVO Qvantig injection takes 3-5 minutes* compared to about 30 minutes for OPDIVO IV, so you will be finished with the administration faster.* For most people, the frequency of appointments will be the same. For example, if you currently receive an infusion of OPDIVO IV every 4 weeks, you will most likely receive your injection with OPDIVO Qvantig every 4 weeks. Talk to your doctor to see if OPDIVO Qvantig is right for you.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary.
Yes, a study of 495 people with advanced kidney cancer compared OPDIVO Qvantig and OPDIVO IV by measuring the amount of medicine in the bloodstream. The results showed that there were no major differences in the amount of medicine that went into the bloodstream between OPDIVO Qvantig and OPDIVO IV.
The active ingredient in OPDIVO Qvantig is the same as the active ingredient in OPDIVO IV. OPDIVO Qvantig also includes a natural enzyme (hyaluronidase) which helps medicines absorb into the body when injected under the skin.
Your doctor can help you decide at any time during your treatment if you can switch to OPDIVO Qvantig from OPDIVO IV. You and your doctor can work together to decide if OPDIVO Qvantig may be right for you.
Please follow up with your insurance company about your coverage for OPDIVO Qvantig injections.
BMS Access Support® is committed to helping you access your prescribed BMS medications. We offer coverage assistance to support medication access as well as financial support options and educational resources to support you throughout your treatment journey. Upon your request, BMS Access Support® may be able to help you review your insurance benefits and understand your coverage for your medication. If your insurer requires prior authorization, BMS Access Support® may be able to provide you and your doctor information about this requirement.
To learn more, ask your doctor, visit BMSAccessSupport, or call BMS Access Support at 1-800-861-0048, 8 am to 8 pm ET, Monday - Friday.
Download BMS Access Support brochure for details.
Preparing for your OPDIVO Qvantig appointment
Your appointment will be similar to an OPDIVO IV appointment. Depending on decisions that you and your healthcare team have made about your treatment plan, your OPDIVO Qvantig appointment will generally have a few parts.
Before your immunotherapy injection: Your healthcare team will do blood tests to check you for side effects
Receiving your immunotherapy injection: Injection time is 3-5 minutes,* though actual time in the clinic may vary
After your immunotherapy injection: Your healthcare team may monitor you for side effects
The time between treatments will vary from 2-4 weeks. Your healthcare team will decide the time between doses and how many treatments you will receive.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary.
It’ll be best for you and your healthcare team if you wear loose-fitting clothing and are comfortable. That way, your healthcare team can easily access your stomach area (abdomen) or thigh area to administer your injection. You may want to wear a large T-shirt, shorts, sweatpants, or something similar.
- Is OPDIVO Qvantig approved for my type of cancer?
- Will I receive this treatment at an infusion center or a different location?
- How should I prepare for my injection appointment?
- How often will I receive treatment?
- Will this treatment affect my daily life in any way?
- How do I know if the treatment is working?
- What are potential side effects that I may experience?
Get information on pricing
This information is not a substitute for talking to your healthcare provider because they are the best source of information about your condition.
Save the OPDIVO Qvantig FAQs for future reference
Sign up for support
Learn about the complimentary OPDIVO with You support program
Side effects tracker
Track your symptoms and other important information so that you can proactively manage potential side effects with your doctor
Medication guide
See which cancer types can be treated with OPDIVO Qvantig and possible side effects
Summary of Warnings and Precautions
Other Important Facts
OPDIVO Qvantig®, OPDIVO®, and YERVOY® (ipilimumab) can cause problems that can sometimes become serious or life-threatening and can lead to death. Serious side effects may include lung problems; intestinal problems; liver problems; hormone gland problems; kidney problems; skin problems; eye problems; problems in other organs and tissues; and complications of stem cell transplant, including graft-versus-host disease (GVHD), that uses donor stem cells (allogeneic). Call or see your healthcare provider right away for any new or worsening signs or symptoms. OPDIVO is associated with severe infusion reactions. See full ISI for OPDIVO and OPDIVO Qvantig below.
Important Facts About OPDIVO® (nivolumab) and OPDIVO + YERVOY® (ipilimumab)This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY. Your healthcare team can work with you to help answer any questions you may have about these medications. Keep this information in a safe place so you can refer to it before and during your treatment.
Look out for the following icons as you read:
Talk to yourhealthcare team
Call a healthcareprovider right away
Helpful informationto remember
OPDIVO and YERVOY are medicines that may treat certain cancers by working with your immune system. OPDIVO and YERVOY can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. Some of these problems may happen more often when OPDIVO is used in combination with another therapy.
A serious side effect is a side effect that can sometimes become severe or life-threatening, and can lead to death. They may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
Lung problems — Things to look out for may include:
- cough
- shortness of breath
- chest pain
Intestinal problems — Things to look out for may include:
- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdominal) pain or tenderness
Liver problems — Things to look out for may include:
- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal
Hormone gland problems — Things to look out for may include:
- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems — Things to look out for may include:
- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite
Skin problems — Things to look out for may include:
- rash
- itching
- skin blistering or peeling
- swollen lymph nodes
- painful sores or ulcers in the mouth or nose, throat, or genital area
- fever or flu-like symptoms
Eye problems — Things to look out for may include:
- blurry vision, double vision, or other vision problems
- eye pain or redness
Problems can also happen in other organs and tissues. These are not all the signs and symptoms of immune system problems that can happen with OPDIVO and YERVOY. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:
- Chest pain, irregular heartbeat, shortness of breath, swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising
Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ transplant that you have had.
What are the possible side effects of OPDIVO + YERVOY?
OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:
See the previous section, "What is the most important information I should know about OPDIVO + YERVOY?"
Severe infusion reactions — Things to look out for may include:
- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feel like passing out
- fever
- back or neck pain
Complications, including graft-versus-host disease (GVHD), of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO or YERVOY. Your healthcare provider will monitor you for these complications.
What are the most common side effects?
The most common side effects of OPDIVO when used alone include:
- feeling tired
- rash
- pain in muscles, bones, and joints
- itching
- diarrhea
- nausea
- weakness
- cough
- shortness of breath
- constipation
- decreased appetite
- back pain
- upper respiratory tract infection
- fever
- headache
- stomach-area (abdominal) pain
- vomiting
- urinary tract infection
The most common side effects of OPDIVO when used in combination with YERVOY include:
- feeling tired
- diarrhea
- rash
- itching
- nausea
- pain in muscles, bones, and joints
- fever
- cough
- decreased appetite
- vomiting
- stomach-area (abdominal) pain
- shortness of breath
- upper respiratory tract infection
- headache
- low thyroid hormone levels (hypothyroidism)
- constipation
- decreased weight
- dizziness
The most common side effects of OPDIVO when used in combination with YERVOY and chemotherapy include:
- feeling tired
- pain in muscles, bones, and joints
- nausea
- diarrhea
- rash
- decreased appetite
- constipation
- itching
The most common side effects of OPDIVO when used in combination with chemotherapy include:
- nausea
- feeling tired
- pain in muscles, bones and joints
- constipation
- decreased appetite
- rash
- vomiting
- numbness, pain, tingling, or burning in your hands and feet
The most common side effects of OPDIVO when used in combination with cabozantinib include:
- diarrhea
- feeling tired or weak
- liver problems
- rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet
- mouth sores
- rash
- high blood pressure
- low thyroid hormone levels
- pain in muscles, bones, and joints
- decreased appetite
- nausea
- change in the sense of taste
- stomach-area (abdominal) pain
- cough
- upper respiratory tract infection
The most common side effects of OPDIVO when used in combination with fluoropyrimidine- and platinum-containing chemotherapy include:
- nausea
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- constipation
- mouth sores
- diarrhea
- vomiting
- stomach-area (abdominal) pain
- pain in muscles, bones, and joints
These are not all the possible side effects. Talk to your healthcare team or pharmacist for more information. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088.
What should I discuss with my healthcare team before receiving OPDIVO or YERVOY?
Important Facts About OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy)
This is a summary of important information that you need to know about OPDIVO Qvantig. Your healthcare team can work with you to help answer any questions you may have about this medication. Keep this document in a safe place, so you can refer to it before and during your treatment.
Look out for the following icons as you read:
Talk to yourhealthcare team
Call a healthcareprovider right away
Helpful informationto remember
OPDIVO Qvantig is a medicine that may treat certain cancers by working with your immune system. OPDIVO Qvantig can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. Some of these problems may happen more often when OPDIVO Qvantig is used in combination with another therapy.
A serious side effect is a side effect that can sometimes become severe or life-threatening and can lead to death. They may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
Lung problems — Things to look out for may include:
- cough
- shortness of breath
- chest pain
Intestinal problems — Things to look out for may include:
- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdominal) pain or tenderness
Liver problems — Things to look out for may include:
- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal
Hormone gland problems — Things to look out for may include:
- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems — Things to look out for may include:
- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite
Skin problems — Things to look out for may include:
- rash
- itching
- skin blistering or peeling
- swollen lymph nodes
- painful sores or ulcers in the mouth or nose, throat, or genital area
- fever and flu-like symptoms
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with OPDIVO Qvantig.
Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ transplant that you have had.
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO Qvantig. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.
What are the most common side effects of OPDIVO Qvantig?
The most common side effects of OPDIVO Qvantig when used alone in people with renal cell carcinoma include:
- pain in muscles, bones, and joints
- feeling tired
- itchy skin
- rash
- low thyroid hormone levels
- diarrhea
- cough
- stomach area (abdominal) pain
The most common side effects observed with nivolumab given into the vein (intravenous nivolumab), which may be experienced with OPDIVO Qvantig, are shown below.
The most common side effects of intravenous nivolumab when used alone include:
- feeling tired or weak
- rash
- pain in muscles, bones, and joints
- itchy skin
- diarrhea
- nausea
- weakness
- cough
- shortness of breath
- constipation
- decreased appetite
- back pain
- upper respiratory tract infection
- fever
- headache
- stomach-area (abdominal) pain
- vomiting
- urinary tract infection
The most common side effects of intravenous nivolumab when used in combination with cabozantinib as the first treatment for advanced RCC include:
- diarrhea
- feeling tired
- liver problems. See "What is the most important information I should know about OPDIVO Qvantig?"
- rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet
- mouth sores
- rash
- high blood pressure
- low thyroid hormone levels
- pain in muscles, bones, and joints
- decreased appetite
- nausea
- change in sense of taste
- stomach area (abdominal) pain
- cough
- upper respiratory tract infection
The most common side effects of intravenous nivolumab when used in combination with platinum-containing chemotherapy and another chemotherapy medicine before having surgery for NSCLC include:
- nausea
- constipation
- feeling tired
- decreased appetite
- rash
The most common side effects of intravenous nivolumab when used in combination with cisplatin and gemcitabine to treat urothelial cancer include:
- nausea
- feeling tired
- pain in muscles, bones, and joints
- constipation
- decreased appetite
- rash
- vomiting
- numbness, pain, tingling, or burning in your hands or feet
The most common side effects of intravenous nivolumab when used in combination with fluoropyrimidine and platinum-containing chemotherapy to treat esophageal cancer and gastric cancer include:
- nausea
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- constipation
- mouth sores
- diarrhea
- vomiting
- stomach area (abdominal) pain
- pain in muscles, bones, and joints
These are not all of the possible side effects of OPDIVO Qvantig.
What should I discuss with my healthcare team before receiving OPDIVO Qvantig?
How will I receive OPDIVO Qvantig?
There are 3 parts to an OPDIVO Qvantig appointment:
Before your injection:
Receiving your injection:
After your injection:
What should I do if I miss an appointment?
See Indications
For certain adults with advanced kidney cancer (renal cell carcinoma)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma, MSI-H or dMMR metastatic colorectal cancer, or cHL.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone as a first treatment for certain adults with kidney cancer that has spread (advanced renal cell carcinoma), after completing combination treatment with intravenous nivolumab and ipilimumab.
It is not known if OPDIVO QVANTIG is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO QVANTIG is safe and effective in children for the treatment of any other cancers.
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with cabozantinib as a first treatment for adults with kidney cancer that has spread (advanced renal cell carcinoma). Please read the Patient Information that comes with cabozantinib.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with previously treated advanced kidney cancer (renal cell carcinoma)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.
It is not known if OPDIVO Qvantig is safe and effective in children.
For certain people with advanced melanoma
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults and children 12 years of age and older who weigh 66 pounds (30 kg) or more with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults and children 12 years of age and older who weigh 66 pounds (30 kg) or more with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma), after completing combination treatment with intravenous nivolumab and ipilimumab.
It is not known if OPDIVO QVANTIG is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO QVANTIG is safe and effective in children for the treatment of any other cancers.
For certain people to help prevent Stage IIB, Stage IIC, Stage III or Stage IV melanoma from coming back after it has been completely removed by surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults and children 12 years and older with Stage IIB, Stage IIC, Stage III or Stage IV melanoma to help prevent melanoma from coming back after it has been completely removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults and children 12 years of age and older who weigh 66 pounds (30 kg) or more with Stage IIB, Stage IIC, Stage III or Stage IV melanoma to help prevent melanoma from coming back after it has been completely removed by surgery.
It is not known if OPDIVO QVANTIG is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO QVANTIG is safe and effective in children for the treatment of any other cancers.
For adults with previously treated advanced esophageal squamous cell cancer
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to completely remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
For previously untreated adults with advanced or metastatic esophageal squamous cell cancer (ESCC)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum as a first treatment for adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery or has spread, and your tumors are positive for PD-L1.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery or has spread, and your tumors are positive for PD-L1.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum as a first treatment to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery or has spread and your tumors are positive for PD-L1.
For certain previously untreated adults with advanced gastric, gastroesophageal junction, and esophageal adenocarcinomas
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric cancer), cancer where the esophagus joins the stomach (gastroesophageal junction cancer), and with esophageal adenocarcinoma when your cancer cannot be removed with surgery or has spread, and your tumors are positive for PD-L1.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric), junction between the stomach and esophagus (gastroesophageal junction), and esophagus that is a type called esophageal adenocarcinoma and cannot be removed with surgery or has spread and your tumors are positive for PD-L1.
For previously untreated adults with urinary tract cancer (urothelial carcinoma) that has spread or cannot be removed by surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment when your urinary tract cancer has spread (metastatic) or cannot be removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment for adults whose urinary tract cancer has spread (metastatic) or cannot be removed by surgery.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with a type of bladder or urinary tract cancer (urothelial carcinoma) to help prevent it from coming back after it was removed by surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with previously treated advanced cancer in the bladder or urinary tract (urothelial carcinoma)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis) [urothelial carcinoma] when it has spread (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis) [urothelial carcinoma] when it has spread (locally advanced or metastatic) and you have received chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.
It is not known if OPDIVO Qvantig is safe and effective in children.
For certain adults with advanced non-small cell lung cancer (NSCLC)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early stage lung cancer (called non-small cell lung cancer) that does not have an abnormal EGFR or ALK gene and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with early-stage non-small cell lung cancer (NSCLC) before surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with previously treated advanced non-small cell lung cancer
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread and you have received chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also received an EGFR or ALK inhibitor medicine and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread and you have received chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also received a FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults with previously treated squamous cell carcinoma of the head and neck
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have received chemotherapy that contains platinum and it did not work or is no longer working.
It is not known if OPDIVO Qvantig is safe and effective in children.
For adults and children 12 years of age and older with advanced MSI-H/dMMR CRC
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine that may be used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that cannot be removed with surgery, or has spread, and is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab and hyaluronidase-nvhy) is a prescription medicine used alone to treat adults and children 12 years of age and older who weigh 66 pounds (30 kg) or more with a type of colon or rectal cancer (colorectal cancer or CRC), after completing combination treatment with intravenous nivolumab and ipilimumab, when your cancer cannot be removed with surgery, or has spread, and is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
It is not known if OPDIVO Qvantig is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer.
OPDIVO Qvantig (120 mg/2,000 units per mL) is an injection for subcutaneous use.
For people whose CRC has spread to other parts of the body (metastatic); has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; and is MSI-H or dMMR
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine that may be used alone to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread, and is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab and hyaluronidase-nvhy) is a prescription medicine that may be used alone to treat adults and children 12 years of age and older who weigh 66 pounds (30 kg) or more with a type of colon or rectal cancer (colorectal cancer or CRC) that has spread, is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working.
It is not known if OPDIVO Qvantig is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer.
OPDIVO Qvantig (120 mg/2,000 units per mL) is an injection for subcutaneous use.
For adults with liver cancer (hepatocellular carcinoma)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of liver cancer called hepatocellular carcinoma that cannot be removed by surgery or has spread.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab and hyaluronidase-nvhy) is a prescription medicine used alone as a first treatment for adults with a type of liver cancer called hepatocellular carcinoma (HCC) after completing combination treatment with intravenous nivolumab and ipilimumab, when your cancer cannot be removed with surgery or has spread.
OPDIVO Qvantig (120 mg/2,000 units per mL) is an injection for subcutaneous use.
For adults with liver cancer (hepatocellular carcinoma) who have received treatment with sorafenib
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with a type of liver cancer called hepatocellular carcinoma (HCC) when your liver cancer cannot be removed by surgery or has spread, and you have received prior treatment with sorafenib.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig® (nivolumab and hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with a type of liver cancer called hepatocellular carcinoma (HCC) after completing combination treatment with intravenous nivolumab and ipilimumab when your cancer cannot be removed with surgery or has spread, and you have received prior treatment with sorafenib.
OPDIVO Qvantig (120 mg/2,000 units per mL) is an injection for subcutaneous use.
For adults with classical Hodgkin lymphoma (cHL)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used alone to treat adults with a type of blood cancer called classical Hodgkin lymphoma (cHL) if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the medicine brentuximab vedotin, or if you received at least 3 kinds of treatment including an autologous stem cell transplant.
It is not known if OPDIVO is safe and effective in children.
For adults newly diagnosed with malignant pleural mesothelioma (MPM)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.